From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: 2-FEA
Chemical Nomenclature
Common names 2-FEA
Substitutive name 2-Fluorethamphetamine
Systematic name N-Ethyl-1-(2-fluorophenyl)propan-2-amine
Class Membership
Psychoactive class Entactogen / Stimulant
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 15 mg
Light 20 - 30 mg
Common 30 - 40 mg
Strong 40 - 60 mg
Heavy 60 mg +
Total 1 - 2.5 hours
Onset 5 - 15 minutes
Come up 5 - 10 minutes
Peak 30 - 60 minutes
Offset 30 - 60 minutes
After effects 1 - 3 hours

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


2-Fluoroethamphetamine (2-FEA) is a novel stimulant substance of the amphetamine class that produces classical stimulant effects such as stimulation, enhanced focus and euphoria when administered.

The exact effects of 2-FEA are not well known by its users with anecdotal reports suggesting only minimal activity and possible serotonergic qualities.

2-FEA is sold on the online research chemical market. It is strongly advised to use harm reduction practices if using this substance.


2-Fluoroethamphetamine (2-FEA) is a synthetic molecule of the substituted amphetamine class. Molecules of the amphetamine class contain a phenethylamine core featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain with an additional methyl substitution at Rα (i.e., amphetamines are alpha-methylated phenethylamines). 2-FEA contains an ethyl group bound to the terminal amine RN of the amphetamine core.

2-FEA is the N-ethylated homolog of 2-FA (2-fluoroamphetamine).


2-FEA has not yet been formally studied to the same extent as traditional amphetamines. Currently, it is assumed that it most likely acts primarily as a triple reuptake inhibitor, and that it releases the neurotransmitters: serotonin, dopamine, and norepinephrine. 2-FEA likely creates it effects by acting as a releasing agent of said neurotransmitters and/or by binding to- and partially blocking the transporter proteins that normally clear substances from the synaptic cleft, after they have fulfilled their function of conducting a neural impulse.[1]

Subjective effects

The effects of 2-FEA appear to be very subtle and difficult to characterize. Some reports suggest it is relatively mild and free of side effects in a similar fashion to 2-FA, while others note an increase in physical side effects or serotonergic activity reminiscent of 3-FEA.

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Visual effects

Cognitive effects

After effects
Aftereffects (3).svg

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 2-FEA use do not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 2-FEA has a very limited history of human usage.

Anecdotal reports from those who have tried 2-FEA suggest that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself or using it sparingly (but nothing can be completely guaranteed).

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

As with other stimulants, the chronic use of 2-FEA can be considered moderately addictive with a high potential for abuse and is capable of causing psychological dependence among certain users. When addiction has developed, cravings and withdrawal effects may occur if a person suddenly stops their usage.

Tolerance to many of the effects of 2-FEA develops with prolonged and repeated use. This results in users having to administer increasingly large doses to achieve the same effects. After that, it takes about 3 - 7 days for the tolerance to be reduced to half and 1 - 2 weeks to be back at baseline (in the absence of further consumption). 2-FEA presents cross-tolerance with all dopaminergic stimulants, meaning that after the consumption of 2-FEA all stimulants will have a reduced effect.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.

Legal status


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

2-FEA is currently a gray area compound within all parts of the world, meaning its regulation lies in a legal gray area and that it is not known to be specifically illegal ("scheduled") within any country. However, people may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.

  • Canada: 2-FEA would be considered Schedule I as it is an analogue of Amphetamine.[4]
  • Germany: 2-FEA is controlled under the NpSG (New Psychoactive Substances Act)[5] as of November 26, 2016.[6] Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.[7]
  • New Zealand: 2-FEA is an amphetamine analogue, so is a Schedule 3 controlled substance in New Zealand.[8]
  • The Netherlands: 2-FEA is currently legal, but it is part of a substance group that may be banned soon as part of a recently passed law on New Psychoactive Substances (NPS). [9]
  • Switzerland: 2-FEA can be considered a controlled substance as a defined derivative of a-methylphenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.[10]
  • United Kingdom: 2-FEA is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.[11]

See also

External links


  1. Tessel, R. E., Woods, J. H. (May 1978). "Substituted N-ethylamphetamine self injection responding in the rhesus monkey: structure-activity relationships". The Journal of Pharmacology and Experimental Therapeutics. 205 (2): 274–281. ISSN 0022-3565. 
  2. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. eISSN 1937-6995. ISSN 1556-9039. OCLC 163567183. 
  3. Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210Freely accessible. eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647. 
  4. Branch, L. S. (2022), Consolidated federal laws of Canada, Controlled Drugs and Substances Act 
  5. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 19, 2019. 
  6. "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 19, 2019. 
  7. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 19, 2019. 
  8. Misuse of Drugs Act 1975 No 116 (as at 01 July 2022), Public Act – New Zealand Legislation 
  9. Wijziging van de Opiumwet in verband met het toevoegen van een derde lijst met als doel het tegengaan van de productie van en de handel in nieuwe psychoactieve stoffen en enkele andere wijzigingen (Dutch), 2024 
  10. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  11. Misuse of Drugs Act 1971